You are here: People >> Board

Overview

Management structure of Equinox Pharma

Board

Members of the board of Equinox Pharma

Staff

Staff and researchers employed by Equinox Pharma

Board of Equinox Pharma

  • Dr. Anthony D. Baxter
  • Professor Paul S. Freemont
  • Professor Stephen H. Muggleton
  • Professor Michael J.E. Sternberg
  • Farad Azima



      •  

      Dr. Anthony D. Baxter

      Executive Chairman

      Dr. Baxter CChem, FRSC is the current CEO of AIM-listed Cyprotex PLC which specialises in high quality ADMET (Absorption Distribution Metabolism Excretion Toxicology) screening services for the pharmaceutical and agrochemical industries. He has over 25 years experience in management and research within the pharmaceutical, biotech chemistry service and instrumentation industries, mainly in the areas of drug discovery, medicinal chemistry, combinatorial chemistry and compound synthesis.

      Before Cyprotex PLC, Dr. Baxter was CEO of deltaDOT Ltd, a company which designs and manufactures separation instruments for drug discovery. Prior to deltaDOT Ltd, he was: one of the founders and CEO of Argenta Discovery Ltd, a specialist medicinal chemistry company providing world-class services to the pharmaceutical industry; CSO of Oxford Asymmetry International Ltd , where he set up and managed the Discovery Services Division; Director of Combinatorial Chemistry at Oxford Diversity Ltd; Research Manager at Ciba UK Central Research Laboratories where he managed Ciba blue-sky research interests; Team Leader at Glaxo Group Research. He has notable scientific success in assisting the development of marketed drugs, Lotronex, Abacavir, Lamivudine and in the discovery of advanced clinical development candidates for Curis, Serono, GSK, Ciba and Argenta.

      Dr. Baxter completed his PhD with Prof. Stan Roberts on prostaglandin chemistry at Salford University. His main interests are the development of new chemical entities, particularly antivirals and in metabolic disease, new chemical technologies including solid phase synthesis and robotics, and antisense and carbohydrate chemistry.

       

      Professor Stephen H. Muggleton

      Non-executive Director and co-founder

      Professor Muggleton BSc, PhD, FAAAI, FBCS, FIET, FREng is the Director of the Imperial College Computational Bioinformatics Laboratory, Director of Modelling at the Centre for Integrative Systems Biology and Bioinformatics at Imperial College (CISBIO), Director of the Syngenta University Innovation Centre at Imperial College and holds the Royal Academy of Engineering/Microsoft Research Chair in Machine Learning at the Department of Computing, Imperial College London. His previous posts were: Joint Research Council Chair in Bioinformatics, Imperial College London; Chair of Machine Learning, University of York; Reader in Machine Learning, EPSRC Advanced Research Fellow and Head of the Machine Learning Group, Computing Laboratory, University of Oxford; EPSRC Post-doctoral Fellow and Turing Institute Research Fellow at the Turing Institute, Glasgow.

      His research interests are related to the development of general, logic-based approaches to machine learning, especially with applications to predictive modelling problems in medicinal chemistry and biology.

       

      Professor Michael J.E. Sternberg

      Non-executive Director and co-founder

      Professor Sternberg MA, MSc, DPhil, FSB is the Director of the Imperial College Centre for Bioinformatics and the Director of CISBIO at Imperial College London. He holds the Chair of Structural Bioinformatics at Imperial College. His previous posts were: Head of Biomolecular Modelling Laboratory, Cancer Research UK; Lecturer and Research Fellow in the Crystallography Department, Birkbeck College; Postdoctoral and Graduate research in Oxford.

      His research interest is the development of novel approaches and principles for the computer modelling of biomolecular structure and function applied to proteins, small molecules, and biological networks. His group has developed many programs which are widely used by the community, most notably the PHYRE Protein Structure Prediction Server, which has had over half a million hits.

       

      Professor Paul S. Freemont

      Non-executive Director and co-founder

      Professor Freemont BSc, PhD is the head of the Molecular Biosciences Division, holds the Chair of Protein Crystallography, and is co-Director of the EPSRC Centre for Synthetic Biology and Innovation, all at Imperial College. His previous posts were: Director of the Imperial College Centre for Structural Biology, Head of Molecular Structure and Function Laboratory, Cancer Research UK; Postdoctoral research fellow in the Department of Molecular Biophysics and Biochemistry at Yale University and graduate student at the University of Aberdeen.

      His research interests are in determining relationships between macromolecular structure and function using experimental methods that include protein crystallography, NMR and Cryo-Electron Microscopy. Recently he has developed research interests in Synthetic Biology, an emerging field that aims to design and engineer of new biology systems. Together with Professor Richard Kitney, he has established the EPSRC Centre for Synthetic Biology and Innovation at Imperial College London, the first UK centre for Synthetic Biology. He was elected to the European Molecular Biology Organisation in 2008.

       

      Farad Azima

      Non-executive Director

      Farad Azima is an industrialist, technology entrepreneur, and philanthropist. An alumnus of Leeds University, he founded Mission Electronics in 1977. He later headed two UK public companies: Verity Group Plc and NXT Plc; both involved in manufacturing and scientific research, and both listed on the London Stock Exchange.

      He served on the Industrial Advisory Board of Churchill College, Cambridge University, and more recently he was appointed to the Advisory Board of LMEI, School of Oriental & African Studies, London University. He has numerous scientific inventions and international patents in his name, and is currently a director of the NetScientific Group based in Cambridge and New York, as well as Advanced BioSensors of Philadelphia.

      Farad Azima has devoted considerable time to philanthropy and, together with his two children, has founded a UK registered charity, the Azima Foundation (Charities Commission ref: 1094484).